Last updated: August 4, 2026
Feldene is Pfizer’s branded formulation of piroxicam, a nonsteroidal anti-inflammatory drug (NSAID) approved in the U.S. for osteoarthritis and rheumatoid arthritis. Its commercial value has declined sharply because U.S. composition-of-matter and regulatory exclusivity ended decades ago, generic piroxicam is available, and NSAID prescribing has shifted toward products with shorter half-lives or more targeted risk profiles. Pfizer does not publicly report Feldene revenue as a separate product line, so the brand’s current sales cannot be calculated from public financial statements. [1][2]
What is Feldene and how is piroxicam used?
Feldene contains piroxicam, an oxicam-class NSAID that inhibits cyclooxygenase-mediated prostaglandin synthesis. The U.S. label covers relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. The usual adult dose is 20 mg once daily, with 10 mg once daily also listed as an option. [1]
Piroxicam has a long elimination half-life, approximately 50 hours. That supports once-daily dosing but also causes prolonged exposure after adverse events or treatment interruption. The label carries boxed warnings for serious cardiovascular thrombotic events and serious gastrointestinal bleeding, ulceration, and perforation. [1]
Feldene dosage forms and market positioning
| Product |
Active ingredient |
Common strength |
Administration |
Commercial position |
| Feldene capsules |
Piroxicam |
10 mg, 20 mg |
Oral, once daily |
Originator brand |
| Generic piroxicam capsules |
Piroxicam |
10 mg, 20 mg |
Oral, once daily |
Primary U.S. substitute |
| Piroxicam gel or topical products |
Piroxicam |
Varies by market |
Topical |
Country-specific, not equivalent to U.S. Feldene capsules |
The U.S. product is an oral capsule. Topical piroxicam products are marketed in some non-U.S. jurisdictions, but they do not directly compete with Feldene capsules under the same FDA approval.
When did Feldene lose exclusivity?
Feldene lost meaningful U.S. market exclusivity long before the current commercial period. Its New Drug Application was approved in 1982, and generic piroxicam products entered after the relevant innovator exclusivity and patent barriers expired. [1][3]
| Exclusivity category |
Feldene status |
| FDA approval |
Approved in 1982 for arthritis indications |
| New chemical entity exclusivity |
Expired decades ago |
| U.S. composition patent protection |
Expired decades ago |
| U.S. generic competition |
Established |
| Current brand exclusivity |
None identified |
| Biosimilar exclusivity |
Not applicable |
A precise current patent-expiration date is not commercially material because piroxicam has been generic for many years. The relevant protection period ended before the modern generic-entry and Orange Book litigation framework became important to the product’s economics.
What patents protect Feldene today?
No active U.S. patent estate with meaningful market-blocking effect has been identified for the conventional Feldene piroxicam capsule. The product’s commercial protection is therefore based on brand recognition, prescription habits, distribution, and any market-specific trademark rights rather than on active pharmaceutical patent claims.
Orange Book status of Feldene
The FDA Orange Book is the principal U.S. reference for approved drug products, therapeutic-equivalence ratings, and listed patents. Feldene’s conventional piroxicam capsule does not have a commercially relevant active patent position comparable to newer branded drugs with listed formulation or method-of-use patents. [3]
Generic piroxicam products can be approved through the abbreviated new drug application pathway if they demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The principal product-level barrier is therefore regulatory substitution and manufacturing compliance, not patent clearance.
Formulation patents and method-of-use patents
The standard Feldene capsule has no publicly important current formulation-patent strategy. A later patent covering a modified-release, abuse-deterrent, combination, or differentiated delivery system could protect a new piroxicam product, but that would not automatically extend protection for the original Feldene capsule.
Method-of-use claims face similar limits. A patent directed to a new indication, dosing schedule, patient subgroup, or combination would need to support a commercially distinct FDA-approved use. It would not prevent generic substitution for the original osteoarthritis and rheumatoid arthritis indications unless the patented use created a legally enforceable carve-out or other market restriction.
How strong is the Feldene patent estate?
The current Feldene patent estate is weak from a commercial-exclusivity perspective.
| Patent-strength factor |
Assessment |
| Active composition patent |
None of commercial significance identified |
| Active formulation patent |
None of commercial significance identified for standard capsules |
| Method-of-use protection |
No known market-blocking position for core indications |
| Generic substitution risk |
High |
| Patent litigation exposure |
Low |
| Lifecycle-management potential |
Limited for the legacy capsule |
| Manufacturing complexity |
Low to moderate |
| Brand differentiation |
Limited |
The product’s long half-life and established clinical history provide some non-patent differentiation. They do not prevent generic competition.
Which companies are challenging Feldene with generics?
Generic competition is fragmented across manufacturers and distributors. Depending on the market and time period, piroxicam capsules may be supplied by generic-drug companies, contract manufacturers, and pharmacy-label distributors. The principal competitive dynamic is price substitution rather than a branded Paragraph IV challenge.
What is the Paragraph IV risk for Feldene?
Paragraph IV litigation risk is effectively historical rather than current. A Paragraph IV certification challenges an Orange Book-listed patent during an abbreviated new drug application. Because the core Feldene patents expired long ago and the product is already generic, a new Paragraph IV campaign against the original capsule is unlikely to alter market structure. [3][4]
Generic entrants face ordinary FDA requirements:
- Pharmaceutical equivalence
- Bioequivalence
- Current good manufacturing practice compliance
- Labeling consistency
- Adequate supply and quality controls
The major risks are manufacturing failures, FDA inspections, recalls, and supply interruptions. Patent litigation is not the principal barrier.
What is the FDA regulatory status of Feldene?
Feldene remains an FDA-approved prescription NSAID product for osteoarthritis and rheumatoid arthritis. The FDA-approved label contains prominent cardiovascular and gastrointestinal warnings and states that piroxicam should be used at the lowest effective dose for the shortest duration consistent with treatment goals. [1]
Regulatory factors affecting demand
Feldene’s label limits its attractiveness for broad, chronic use:
- The long half-life can extend adverse-event exposure.
- NSAID class warnings apply to cardiovascular and gastrointestinal risks.
- Older adults and patients with cardiovascular, renal, or gastrointestinal comorbidities require careful selection.
- Newer prescribing patterns often favor lower-dose or shorter-acting NSAIDs when clinically appropriate.
These considerations do not remove Feldene from the market. They constrain volume growth and reduce the probability of a major branded relaunch.
How has the Feldene market changed?
Feldene moved through four commercial stages:
| Period |
Market condition |
Financial effect |
| 1980s |
Novel oral NSAID with once-daily dosing |
Originator pricing and exclusivity |
| 1990s |
Generic entry and broader NSAID competition |
Rapid price and share erosion |
| 2000s |
Mature generic market |
Low unit economics |
| 2010s to present |
Chronic legacy product with limited differentiation |
Low strategic priority and limited brand revenue |
The main competitors are not only generic piroxicam products. Feldene also competes with ibuprofen, naproxen, diclofenac, meloxicam, celecoxib, and non-NSAID pain treatments. These alternatives differ in dosing frequency, cardiovascular and gastrointestinal risk, physician familiarity, formulary treatment, and price.
How does Feldene compare with competing NSAIDs?
| Product |
Active ingredient |
Typical commercial advantage |
Key limitation |
| Feldene |
Piroxicam |
Once-daily dosing, established use |
Long half-life and class safety risks |
| Mobic |
Meloxicam |
Once-daily generic alternative |
Similar NSAID safety constraints |
| Celebrex |
Celecoxib |
COX-2 selectivity and differentiated positioning |
Cardiovascular and renal concerns; higher branded value historically |
| Naprosyn/generic naproxen |
Naproxen |
Broad availability and low cost |
Gastrointestinal and renal risks |
| Voltaren/generic diclofenac |
Diclofenac |
Strong anti-inflammatory activity; oral and topical forms |
Cardiovascular, hepatic, and gastrointestinal concerns |
| Advil/Motrin/generic ibuprofen |
Ibuprofen |
Extensive consumer awareness and low price |
Shorter dosing interval |
Piroxicam’s once-daily schedule remains a practical benefit. Its long half-life is less attractive when clinicians prioritize rapid clearance or lower residual exposure.
What is Feldene’s current financial trajectory?
Feldene’s financial trajectory is mature, declining, and low-value relative to Pfizer’s major products. Pfizer reports revenue by broader product and business categories, not as a standalone Feldene line item. Public filings therefore do not provide a verifiable current Feldene revenue figure. [2]
The product’s likely economics are shaped by five factors:
- Generic price substitution
- Limited brand-specific prescribing
- Low promotional investment
- Mature manufacturing and distribution
- Small incremental value from maintaining the legacy brand
The originator may still earn revenue from brand prescriptions in markets where physicians, patients, or reimbursement systems retain a preference for Feldene. That revenue is unlikely to have material influence on Pfizer’s consolidated financial performance.
Revenue exposure for Pfizer
Feldene is not comparable with Pfizer products that have large protected markets, such as oncology, vaccines, immunology, or specialty-care products. Its financial exposure is limited because:
- The product is old.
- Generic alternatives are available.
- There is no active exclusivity period supporting premium pricing.
- The product is not a principal driver of Pfizer’s reported revenue.
- Switching costs are low for most patients and prescribers.
A supply disruption could create short-term wholesale price movement, but it would not create durable market power unless generic supply also contracted.
What licensing deals affect Feldene?
No major recent licensing transaction has been publicly identified as a material driver of Feldene’s economics. Piroxicam is an established small molecule, and the commercial market does not require a specialized biotechnology license or biosimilar partnership.
Potential arrangements in the product’s supply chain may include:
- Local marketing rights
- Contract manufacturing
- Distribution agreements
- Private-label supply
- Country-specific registration rights
These arrangements would affect regional availability and margin allocation but are unlikely to change the global competitive position of the molecule.
Does Feldene face biosimilar risk?
No. Biosimilar regulation applies to biological products, not conventional small-molecule drugs such as piroxicam. Feldene faces generic-drug substitution risk, not biosimilar competition. FDA approval for a generic piroxicam capsule proceeds through the ANDA pathway rather than the 351(k) biosimilar pathway. [3][5]
What patent litigation affects Feldene?
No active, market-defining U.S. patent litigation involving the original Feldene capsule has been identified as a current commercial issue. The principal legal risks are more likely to involve:
- Product liability claims based on NSAID cardiovascular or gastrointestinal risks
- Manufacturing and quality disputes
- Trademark or trade-dress issues
- Contract disputes involving regional distribution
- Regulatory enforcement or recall matters
These issues differ from patent litigation and do not restore exclusivity to the product.
What generic launch scenarios exist for Feldene?
Base case
Generic piroxicam remains widely available, brand Feldene retains a small residual share, and pricing stays compressed. Pfizer maintains limited commercial exposure.
Downside case
Additional generic suppliers enter, payer substitution increases, and Feldene becomes difficult to obtain through routine retail channels. Brand revenue declines toward immaterial levels.
Supply-disruption case
A manufacturing interruption at one or more generic suppliers causes temporary shortages. Feldene could gain short-term demand from prescriber or pharmacy substitution, but the effect would depend on inventory and alternative NSAID availability.
Geographic variation
The U.S. market is highly genericized. In some international markets, Feldene remains a recognized brand and piroxicam is available in oral or topical forms. Pricing, reimbursement, registration status, and local manufacturers vary significantly by country. A global revenue estimate cannot be derived from U.S. approval and patent data alone.
What manufacturing and intellectual-property barriers remain?
Manufacturing piroxicam capsules is less complex than manufacturing biologics, sterile injectables, or complex modified-release systems. Remaining barriers include:
- Active pharmaceutical ingredient qualification
- Impurity and stability control
- Capsule content uniformity
- Bioequivalence documentation
- Good manufacturing practice compliance
- Reliable supply of API and finished dosage forms
These barriers can reduce the number of active suppliers during shortages. They do not create durable patent protection for Feldene.
Key Takeaways
- Feldene is the Pfizer brand for piroxicam, an oral NSAID approved in the U.S. in 1982.
- Core exclusivity and patent protection expired decades ago.
- Generic piroxicam creates high substitution risk and limits pricing power.
- No current market-blocking Feldene formulation or method-of-use patent position has been identified.
- Paragraph IV litigation is not a significant present commercial risk.
- Biosimilar competition does not apply because piroxicam is a small molecule.
- Pfizer does not report Feldene revenue separately, so current product-level sales cannot be verified from public filings.
- The financial trajectory is mature and declining, with limited relevance to Pfizer’s consolidated results.
- Current market value depends more on brand persistence, supply continuity, and regional reimbursement than on intellectual property.
FAQs
Is Feldene still available in the United States?
Feldene remains an FDA-approved piroxicam product, while generic piroxicam capsules are available through the U.S. prescription market. Retail availability can vary by pharmacy, wholesaler, and inventory status. [1][3]
Is piroxicam stronger than ibuprofen or naproxen?
Clinical effectiveness depends on the condition, dose, treatment duration, and patient characteristics. Piroxicam is distinguished by once-daily dosing and a long half-life, not by a universal superiority claim over other NSAIDs.
Can a generic manufacturer launch a piroxicam capsule without a new clinical trial?
Generally, an ANDA applicant can rely on the reference drug’s existing safety and efficacy findings by demonstrating pharmaceutical equivalence and bioequivalence, subject to FDA requirements. [3]
Does Feldene have pediatric exclusivity?
The original Feldene approval is too old for pediatric exclusivity to be a current commercial factor. Any historical exclusivity period would have expired long ago.
Could a new topical piroxicam product revive the Feldene brand?
A topical product could create a differentiated commercial product only if it obtained the required regulatory approval, demonstrated a viable clinical and reimbursement profile, and secured enforceable intellectual-property rights. It would not extend exclusivity for the existing oral capsule automatically.
References
- U.S. Food and Drug Administration. (2023). Feldene (piroxicam) capsules: Prescribing information.
- Pfizer Inc. (2024). Annual report 2023.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certification requirements.
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.
